Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Eurofarma LaboratoriosPrivate | 2 assets: 2 Ph 3 | N0877Phase 3 · Hypertension | None on record |
 Exciva GmbHPrivate | 2 assets: 2 Ph 3 | DeramciclanePhase 2/3 · Alzheimer's Disease | Jan 2029Deramciclane · Phase 2/3 |
 Ferring PharmaceuticalsPrivate | 2 assets: 1 approved, 1 Ph 2 | olamkiceptPhase 2 · Ulcerative ColitisPartial signal | None on record |
| 2 assets: 2 Ph 1 | FHD-286Phase 1 · Acute Myeloid Leukemia | Oct 2027LY4050784 · Phase 1 | |
 Fresenius SE & Co. KGaAFRE · Xetra | 2 assets: 2 approved | Approved assets only | None on record |
 Frontier Biotechnologies688221 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 2 | AlbuvirtidePhase 3 · HIVPartial signal | None on record |
 GC Biopharma Corp.006280 · KOSPI | 2 assets: 2 Ph 3 | Diluted I.V.-Hepabig inj(GC5103)Phase 3 · Chronic Hepatitis B | None on record |
 GH ResearchGHRS · Nasdaq | 2 assets: 2 Ph 2 | Mebufotenin (5-MeO-DMT)Phase 2 · Major Depressive DisorderPartial signal | None on record |
 GPCR Therapeutics, Inc.Private | 2 assets: 2 Ph 2 | Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signal | None on record |
 Galectin Therapeutics Inc.GALT · Nasdaq | 2 assets: 2 Ph 3 | belapectinPhase 2/3 · MASH / NASHPartial signal | None on record |
 GenFleet Therapeutics2595 · HKEX | 2 assets: 1 Ph 3, 1 Ph 2 | GFH375Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027GFH375 · Phase 2 |
 Gilgamesh PharmaceuticalsPrivate | 2 assets: 2 Ph 2 | BlixeprodilPhase 2 · Major Depressive DisorderPartial signal | None on record |
 GlaceumPrivate | 2 assets: 2 Ph 2 | HSG4112Phase 2 · ObesityPartial signal | None on record |
| 2 assets: 1 Ph 3, 1 Ph 2 | UproleselanPhase 3 · Relapsed/Refractory Acute Myeloid Leukemia | Feb 2029CR-001 · Phase 1/2 | |
| 2 assets: 1 Ph 3, 1 Ph 1 | TVAX-008Phase 3 · Chronic Hepatitis B | None on record | |
 GrifolsGRF · BME | 2 assets: 1 Ph 3, 1 Ph 2 | Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3 · Chronic Hepatitis B | None on record |
 Grünenthal GmbHPrivate | 2 assets: 2 approved | Approved assets only | None on record |
 GubraPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | GUB-UCN2Phase 1/2 · Obesity | Dec 2028GUB-UCN2 · Phase 1/2 |
HC Biopharma Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | HC010Phase 2 · Non-Small Cell Lung Cancer | 30 Dec 2026HC010 · Phase 2 |
 HUTCHMEDHCM · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | SavolitinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 18 Jan 2027Savolitinib · Phase 2 |
 HUYABIO International, LLC.Private | 2 assets: 2 Ph 1 | HBI-2376Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2026HBI-2376 · Phase 1 |
 Haleon US HoldingsPrivate | 2 assets: 2 approved | Approved assets only | None on record |
| 2 assets: 1 Ph 3, 1 Ph 2 | SG301Phase 3 · Multiple MyelomaPartial signal | 31 Mar 2027SG301 · Phase 2 | |
 Harmony BiosciencesHRMY · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | Clemizole (EPX-100)Phase 3 · Epilepsy | 1 Nov 2026Clemizole (EPX-100) · Phase 3 |
 Hebei Senlang BiotechnologyPrivate | 2 assets: 2 Ph 2 | SENL103Phase 1/2 · Multiple MyelomaWeak signal | 1 Feb 2028SENL103 · Phase 1/2 |
 Herantis Pharma Plc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | CDNF (cerebral dopamine neurotrophic factor)Phase 1/2 · Parkinson's DiseasePartial signal | None on record |
 HiFiBiO TherapeuticsPrivate | 2 assets: 2 Ph 1 | HFB200301Phase 1 · Non-Small Cell Lung Cancer | Dec 2026HFB200301 · Phase 1 |
 Hua Medicine2552 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | DorzagliatinPhase 3 · Type 2 DiabetesPartial signal | None on record |
 Huabo Biopharm Co.Private | 2 assets: 2 Ph 3 | HB0017Phase 3 · PsoriasisPartial signal | 15 Jan 2027HB0025 · Phase 2 |
 Hummingbird BiosciencePrivate | 2 assets: 2 Ph 2 | ENV-501Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2027ENV-501 · Phase 1/2 |
 Hyundai Pharm004310 · KOSPI | 2 assets: 2 Ph 3 | Candesartan/AmlodipinePhase 3 · Atherosclerotic Cardiovascular Disease | None on record |
 ImmuneOnco Biopharmaceuticals1541 · HKEX | 2 assets: 2 Ph 2 | IMM2510Phase 2 · Non-Small Cell Lung Cancer | 20 May 2027ImmuneOnco anti-PAH candidate (IMC-003) · Phase 1 |
 Immunic, Inc.IMUX · Nasdaq | 2 assets: 1 Ph 3, 1 other | vidofludimus calciumPhase 3 · Multiple Sclerosis | Nov 2026vidofludimus calcium · Phase 3 |
 ImmunityBioIBRX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | HankPhase 2 · Non-Small Cell Lung Cancer | Nov 2026N-803 · Phase 2 |
 Immunocore Holdings plcIMCR · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | brenetafuspPhase 3 · Cutaneous Melanoma | 16 Oct 2027brenetafusp · Phase 3 |
 Inhibikase TherapeuticsIKT · Nasdaq | 2 assets: 2 Ph 2 | Risvodetinib (IkT-148009)Phase 2 · Parkinson's DiseasePartial signal | None on record |
 Inhibrx Biosciences, IncINBX · | 2 assets: 1 Ph 3, 1 other | INBRX-106Phase 2/3 · Head and Neck Squamous Cell Carcinoma | Dec 2028ozekibart · Phase 1 |
 Ironwood PharmaceuticalsIRWD · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | apraglutidePhase 3 · Short Bowel Syndrome | None on record |
 Jade Biosciences, Inc.JBIO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | JADE101Phase 2 · IgA Nephropathy | May 2027JADE101 · Phase 1 |
 Janux TherapeuticsJANX · Nasdaq | 2 assets: 2 Ph 1 | JANX007Phase 1 · Prostate Cancer | Jul 2027JANX007 · Phase 1 |
 JemincarePrivate | 2 assets: 1 Ph 3, 1 Ph 2 | JMKX001899Phase 3 · Non-Small Cell Lung Cancer | 31 Dec 2027JMKX001899 · Phase 3 |
| 2 assets: 1 Ph 3, 1 Ph 1 | VCT220Phase 3 · ObesityReliable signal | 30 Oct 2026VCT220 · Phase 2 | |
| 2 assets: 1 Ph 2, 1 Ph 1 | ACC017Phase 1/2 · HIVPartial signal | 30 Jun 2027ACC017 · Phase 1/2 | |
| 2 assets: 2 Ph 3 | ASKC202Phase 3 · Non-Small Cell Lung Cancer | Dec 2026ASKC202 · Phase 1 | |
 Jiangsu Nhwa Pharmaceutical Co., Ltd.002262 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | NH102Phase 2 · Major Depressive DisorderPartial signal | None on record |
 Kailera TherapeuticsKLRA · Nasdaq | 2 assets: 2 Ph 3 | HRS-7535Phase 3 · ObesityReliable signal | Dec 2026HRS-7535 · Phase 2 |
Kainos Medicine284620 · KOSDAQ | 2 assets: 1 Ph 2, 1 Ph 1 | KM-819Phase 2 · Parkinson's DiseasePartial signal | None on record |
 KardiganKARD · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | DanicamtivPhase 3 · Heart FailurePartial signal | Dec 2026Tonlamarsen · Phase 2 |
 Karyopharm TherapeuticsKPTI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | EltanexorPhase 1/2 · Multiple MyelomaWeak signal | Dec 2026Selinexor · Phase 2/3 |
 Korea United Pharm033270 · KOSPI | 2 assets: 2 Ph 3 | UI022/UI023Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 Kowa Company, Ltd.Private | 2 assets: 1 Ph 3, 1 Ph 2 | PemafibratePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 31 Jul 2027Pemafibrate · Approved |
 Kylonova (Xiamen) BiopharmaPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | Kylo-11Phase 2 · Atherosclerotic Cardiovascular Disease | 28 Feb 2027Kylo-11 · Phase 2 |
 Kymera TherapeuticsKYMR · Nasdaq | 2 assets: 2 Ph 2 | KT-474Phase 2 · Hidradenitis Suppurativa | Jun 2027KT-621 · Phase 2 |
 Kyntra BioKYNB · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Oct 2027Roxadustat · Phase 3 |
 Laboratorios Farmacéuticos Rovi, S.A.ROVI · BME | 2 assets: 1 approved, 1 Ph 3 | Risperidone (QUAR)Phase 3 · SchizophreniaWeak signal | None on record |
 Laekna Limited2105 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Oct 2026Afuresertib · Phase 3 |
 Lakefront Biotherapeutics NVLKFT · Nasdaq | 2 assets: 2 Ph 2 | GLPG3667Phase 2 · Dermatomyositis | None on record |
 Lantern Pharma Inc.LTRN · | 2 assets: 1 Ph 3, 1 Ph 2 | LP-300Phase 3 · Non-Small Cell Lung CancerPartial signal | Dec 2026LP-300 · Phase 2 |
| 2 assets: 1 Ph 2, 1 Ph 1 | LT-002-158Phase 1/2 · Atopic Dermatitis | 17 Feb 2028LT-002-158 · Phase 1/2 | |
 Legend Biotech CorporationLEGN · Nasdaq | 2 assets: 1 approved, 1 other | LCAR-F33SMultiple Myeloma | 26 Feb 2027Ciltacabtagene autoleucel · Phase 2 |
 Lexaria BioscienceLEXX · Nasdaq | 2 assets: 2 Ph 1 | DehydraTECH-CBD/semaglutidePhase 1 · ObesityPartial signal | None on record |
 Lexicon PharmaceuticalsLXRX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | PilavapadinPhase 2 · Diabetic Peripheral Neuropathic PainPartial signal | Jan 2027Sotagliflozin (Inpefa) · Phase 3 |
 Liquidia CorporationLQDA · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | L606Phase 3 · Hypertension | Feb 2027Treprostinil (Yutrepia, Liquidia) · Phase 2 |
| 2 assets: 2 Ph 1 | LonitoclaxPhase 1 · Acute Myeloid Leukemia | Dec 2026ZE 50-0134 · Phase 1 | |
 Luminary Therapeutics, Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | LMY-920Phase 2 · Multiple Myeloma | Apr 2029LMY-922 · Phase 1 |
 Lyell Immunopharma, Inc.LYEL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | Rondecabtagene autoleucelPhase 3 · Large B-Cell Lymphoma | Jun 2028LYL273 · Phase 1/2 |
 Lynk PharmaceuticalsPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | LNK01001Phase 3 · Atopic DermatitisReliable signal | Nov 2026LNK01001 · Phase 3 |
 MC2 TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 2 | MC2-25Phase 2 | None on record |
| 2 assets: 2 Ph 3 | 7MW3711Phase 3 · Non-Small Cell Lung Cancer | 31 Dec 20277MW3711 · Phase 1/2 | |
| 2 assets: 1 Ph 1, 1 other | MT-401-OTSPhase 1 · Acute Myeloid Leukemia | Sep 2029MT-401-OTS · Phase 1 | |
 Mayne PharmaMYX · ASX | 2 assets: 2 approved | Approved assets only | None on record |
| 2 assets: 2 Ph 3 | YL201Phase 3 · Non-Small Cell Lung Cancer | Nov 2026YL202 · Phase 2 | |
 Medicenna Therapeutics, Inc.MDNA · TSX | 2 assets: 1 Ph 2, 1 other | MDNA11Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 MediciNova, Inc.MNOV · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | AV411Phase 3 · Amyotrophic Lateral Sclerosis | 31 Dec 2026MN-001 · Phase 2 |
 Mereo BioPharmaMREO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | setrusumabPhase 3 · Osteogenesis Imperfecta | None on record |
 Merus N.V.Private | 2 assets: 1 approved, 1 Ph 2 | MCLA-129Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2026Zenocutuzumab · Phase 2 |
 Merz TherapeuticsPrivate | 2 assets: 2 approved | Approved assets only | None on record |
 MetaViaMTVA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | DA-1241Phase 2 · Type 2 DiabetesPartial signal | 9 Nov 2026DA-1726 · Phase 1 |
 Mirador TherapeuticsPrivate | 2 assets: 2 Ph 2 | MT-201Phase 2 · Ulcerative Colitis | 12 Nov 2026MT-201 · Phase 1 |
 Mirum Pharmaceuticals, Inc.MIRM · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | volixibatPhase 2 · Primary Sclerosing Cholangitis | Jan 2027volixibat · Phase 2 |
 Molecular PartnersMOLN · | 2 assets: 1 Ph 1, 1 other | MP0533Phase 1 · Acute Myeloid Leukemia | None on record |
| 2 assets: 1 Ph 2, 1 Ph 1 | MRT-2359Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2027MRT-2359 · Phase 2 | |
 Myeloid TherapeuticsPrivate | 2 assets: 2 Ph 1 | MT-302Phase 1 · Non-Small Cell Lung Cancer | 31 Jan 2027MT-304 · Phase 1 |
 NImmune BiopharmaPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | omilancorPhase 2 · Ulcerative ColitisPartial signal | None on record |
| 2 assets: 1 Ph 3, 1 Ph 1 | SH-1028Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026SH009 · Phase 1 | |
 Nektar TherapeuticsNKTR · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | rezpegaldesleukinPhase 3 · Atopic DermatitisPartial signal | May 2028rezpegaldesleukin · Phase 3 |
 Neonc Technologies, Inc.NTHI · Nasdaq | 2 assets: 1 Ph 2, 1 other | NEO212Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027NEO212 · Phase 1/2 |
 Neumora Therapeutics, Inc.NMRA · Nasdaq | 2 assets: 1 Ph 1, 1 other | NMRA-323511Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Neurim Pharmaceuticals Ltd.Private | 2 assets: 2 Ph 3 | Melatonin prolonged-releasePhase 3 | None on record |
 NovaBridge BiosciencesNBP · Nasdaq | 2 assets: 2 Ph 2 | olamkiceptPhase 2 · Ulcerative ColitisPartial signal | Dec 2026givastomig · Phase 1 |
 Nuravax, Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | AV-1959RPhase 2 · Alzheimer's DiseasePartial signal | 1 Apr 2027DUVAX · Phase 1 |
 Nuvation BioNUVB · NYSE | 2 assets: 1 approved, 1 Ph 3 | safusidenibPhase 3 · Glioma | 2 Feb 2027Taletrectinib · Phase 1 |
| 2 assets: 2 Ph 1 | NCR201Phase 1 · Parkinson's Disease | 31 Dec 2028NCR300 · Phase 1 | |
 OSE ImmunotherapeuticsOSE · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | OSE2101Phase 3 · Non-Small Cell Lung CancerPartial signal | 15 Dec 2027OSE2101 · Phase 3 |
| 2 assets: 1 Ph 3, 1 Ph 1 | PalazestrantPhase 3 · HR+/HER2- Metastatic Breast CancerWeak signal | 31 Oct 2026Palazestrant · Phase 3 | |
 Omeros CorporationOMER · Nasdaq | 2 assets: 1 Ph 2, 1 other | zaltenibartPhase 2 · Paroxysmal Nocturnal Hemoglobinuria | None on record |
 OncoC4, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 1 | GotistobartPhase 3 · Non-Small Cell Lung Cancer | 30 Nov 2026Gotistobart · Phase 1/2 |
 Orca Biosystems, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 2 | Orca-TPhase 3 · Acute Myeloid Leukemia | Nov 2027Orca-T · Phase 2 |
 Orion CorporationORNBV · Nasdaq Helsinki | 2 assets: 1 approved, 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 |
 OrsoBioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | TLC-2716Phase 2 · Atherosclerotic Cardiovascular Disease | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).